Pfizer Inc.
Pfizer Research Technology Center (RTC)
620 Memorial Drive
Cambridge
Massachusetts
02139
United States
Tel: 617-551-3000
Fax: 617-551-3111
Website: http://www.pfizer.com/
About Pfizer Inc.
The Pfizer Research Technology Center (RTC) in Cambridge, MA houses cutting edge research groups focused on RNAi therapeutics, Systems Biology and Biological Profiling, Regenerative Medicine and Computational Sciences.
Headquartered at the RTC, and comprising research groups in Cambridge and Düsseldorf, the goal of Pfizer RNAi Therapeutics is clear - delivering RNAi therapies to meet our patient needs and in doing so helping Pfizer become a top tier biotherapeutics company.
Pfizer Regenerative Medicine is collaborating with local experts to develop Stem Cell Therapies to treat diseases.
The Systems Biology, Biological Profiling and Computational Sciences groups are using their niche skills and expertise to focus on increasing the effectiveness of the research process through better target selection, reduced attrition and the ability to manipulate and manage data to support the research process.
Without the constraints of a therapeutic area portfolio, RTC colleagues are free to apply cutting-edge techniques and technologies with broad utility across different therapeutic areas.
The RTC is located in one of the richest scientific environments in the world, surrounded by more than 300 biotechnology companies and thousands of scientific innovators in world-leading research hospitals and academic institutions. A key element in the success of the RTC is the growing and dynamic portfolio of partnerships with these innovators, focused on addressing the strategic needs of the site and of Pfizer's research division.
The RTC aims to balance the strength of Pfizer R&D with the nimble feel of a small biotech, and creates an exciting and team-based scientific environment for 150 colleagues, with a wide range of scientific skills and experience. The working environment emphasizes collaboration and cooperation with most scientific questions solved through the work of a cross-disciplinary team. The unique working environment - truly a small biotech with the backing of the largest research budget in the industry - supports the unique science of the site.
For more information, please visit www.pfizercambridge.com
113 articles about Pfizer Inc.
-
Susan Desmond-Hellmann Elected to Pfizer’s Board of Directors
4/2/2020
Pfizer Inc. (NYSE: PFE) today announced the election of Dr. Susan Desmond-Hellmann to its Board of Directors, effective immediately. Dr. Desmond-Hellmann, age 62, was also appointed to the Governance & Sustainability Committee and the Science and Technology Committee of Pfizer’s Board. Dr. Desmond-Hellmann served as Chief Executive Officer of the Bill & Melinda Gates Foundation from 2014 until 2020, where she overs
-
Pfizer Receives European Approval for Oncology Biosimilar, RUXIENCE™ (rituximab)
4/2/2020
Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has approved RUXIENCE™ (rituximab), a monoclonal antibody (mAb) and biosimilar to MabThera® (rituximab), for the treatment of non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), and pemphigus vulgaris (PV)
-
Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic
4/1/2020
Three leading biopharmaceutical companies have announced programs enabling employees with medical and laboratory expertise to volunteer their services to local healthcare systems and those hardest hit by COVID-19.
-
Pfizer Completes $1.25 Billion Sustainability Bond for Social and Environmental Impact
3/27/2020
Pfizer Inc. (NYSE: PFE) today announced the completion of a $1.25 billion ten-year “sustainability” bond paying interest semi-annually of 2.625 percent and maturing April 1, 2030.
-
A summary of daily biopharma industry news. Please check out stories that are trending on March 27, 2020.
-
Mylan and Pfizer Provide Update Regarding Proposed Combination of Mylan and Upjohn
3/26/2020
Due to global impact of COVID-19 pandemic, transaction now expected to close in the second half of 2020 and Mylan's EGM moved to June 30
-
A summary of daily biopharma industry news. Please check out stories that are trending on March 26, 2020.
-
U.S. FDA Approves Supplemental New Drug Application (sNDA) for Expanded Indication of EUCRISA® (Crisaborole) Ointment, 2%, in Children as Young as 3 Months of Age With Mild-to-Moderate Atopic Dermatitis
3/24/2020
EUCRISA is the first and only 100% steroid-free, topical prescription medication approved for patients as young as 3 months of age in the United States
-
Pfizer and GlaxoSmithKline Announce Joint Venture to Create a Premier Global Consumer Healthcare Company
12/19/2018
Establishes a new focused global consumer healthcare business with the independence and sustainability to deliver significant value
-
Pharma Companies Are Framing Retention Plans
8/21/2007
-
BioSpace, Inc. And Massachusetts Biotechnology Council, Inc. Unveil 2006 Genetown™ Campaign
12/15/2005
-
Drug Companies Launch New Discount Card
1/12/2005
-
Pulmonary Hypertension Association Release: Viagra Study Spotlights Pulmonary Hypertension
11/1/2004